用于抗肿瘤药物预筛选的改良型基因工程大肠杆菌菌株。
Improved genetically modified Escherichia coli strain for prescreening antineoplastic agents.
作者信息
Bartus H R, Mirabelli C K, Auerbach J I, Shatzman A R, Taylor D P, Johnson R K, Rosenberg M, Crooke S T
出版信息
Antimicrob Agents Chemother. 1984 May;25(5):622-5. doi: 10.1128/AAC.25.5.622.
Clinical experience suggests that drugs that interact with and damage DNA are useful in cancer chemotherapy (H. Umezawa , p. 43-72, in V. T. DeVita , Jr., and H. Busch [ed.], Methods in Cancer Research; Cancer Drug Development, vol. XVI, 1979). Prescreening systems for antitumor agents in natural products require assays that are exquisitely sensitive, since the active components are often produced in quantities of micrograms per milliliter or less. One assay used to identify agents that interact with DNA is the biochemical induction assay, utilizing Escherichia coli BR 513 (R. K. Elespuru and R. J. White, Cancer Res. 43:2819-2830, 1983). In this paper we describe a genetic modification of strain BR 513 that displays an expanded spectrum of activity. This strain may provide an improved prescreen for detecting natural products that interact with DNA.
临床经验表明，与DNA相互作用并对其造成损伤的药物在癌症化疗中是有用的（H. 梅泽awa，第43 - 72页，载于V. T. 德维塔，Jr. 和H. 布施 [编]，《癌症研究方法；癌症药物开发》，第十六卷，1979年）。天然产物中抗肿瘤剂的预筛选系统需要极其灵敏的检测方法，因为活性成分的产量通常为每毫升微克级或更低。一种用于鉴定与DNA相互作用的试剂的检测方法是生化诱导检测法，利用大肠杆菌BR 513（R. K. 埃莱斯普鲁和R. J. 怀特，《癌症研究》43:2819 - 2830，1983年）。在本文中，我们描述了BR 513菌株的一种基因改造，该改造显示出更广泛的活性谱。该菌株可能为检测与DNA相互作用的天然产物提供一种改进的预筛选方法。
Zotero 插件